Immune checkpoint inhibitors have reshaped treatment for extensive-stage small cell lung cancer, though their role in limited-stage disease remains uncertain.
|Slideshows|March 1, 2014
Treating Triple-Negative Breast Cancer
Author(s)Lisa A. Carey, MD
This slide deck covers the treatment of triple-negative breast cancer, a heterogeneous disease made up of numerous subtypes, and includes clinical variables that can help with prognosis and guide in treatment choice.
Advertisement
Advertisement
Related to this article
Cosibelimab is now a preferred, category 2A NCCN option for locally advanced CSCC when curative surgery or radiation is not feasible.
Sofetabart mipitecan produced responses in heavily pretreated high-grade ovarian cancer regardless of folate receptor α expression or prior mirvetuximab soravtansine.
The European Commission approved the pembrolizumab-based regimen for resectable MIBC regardless of cisplatin eligibility based on the KEYNOTE-B15 data.
Training AI on data without good representation of underserved populations may unintentionally widen disparities in lung cancer care.
At the BIG10 CRC Summit, Mingjia Li, MD, outlined how pre-operative hemoglobin may signal treatment response in resectable NSCLC.
Experts highlight KEYNOTE-C93, TroFuse-005, and antibody-drug conjugate data in platinum-resistant ovarian cancer at the ESMO Congress 2026.
Nikolai Strusberg, MD, discussed other toxicities of proton vs photon breast RT, practice implications, and next steps in capsular contracture research.
Advertisement
Advertisement
Trending on CancerNetwork
1
The Gynecologic Oncology Data to Watch at ESMO 2026: De-Escalation and ADCs
2
Cancer Vaccine Combinations Improve 1-Year Survival in Second-Line NSCLC
3
Monitoring Anemia and Optimizing Regimen Selection in Resectable NSCLC
4
The Usefulness of Indocyanine Green in Cytoreductive Ovarian Cancer Surgery
5